Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

This study has been completed.
Sponsor:
Collaborators:
Gateway for Cancer Research
University of Southern California
Information provided by (Responsible Party):
Weili Sun, Children's Hospital Los Angeles
ClinicalTrials.gov Identifier:
NCT01861002
First received: May 21, 2013
Last updated: July 29, 2014
Last verified: July 2014

May 21, 2013
July 29, 2014
May 2013
July 2014   (final data collection date for primary outcome measure)
The dose of azacytidine that can be given safely with fludarabine and cytarabine. [ Time Frame: 7 weeks ] [ Designated as safety issue: Yes ]
The incidence of dose limiting toxicity (DLT) will be measured. The maximum tolerated dose will be the highest study dose at which 1 or fewer of six patients experience DLT during cycle 1 of therapy.
Same as current
Complete list of historical versions of study NCT01861002 on ClinicalTrials.gov Archive Site
  • The response rate after treatment. [ Time Frame: 7 weeks ] [ Designated as safety issue: No ]
  • DNA methylation and gene expression before and after treatment with azacytidine. [ Time Frame: 2 years ] [ Designated as safety issue: No ]

    To establish the extent of hypomethylation of peripheral blood (PB) and bone marrow (BM) pre- and post- azacytidine treatment by:

    • LINE-1 methylation assay as a surrogate marker to assess global DNA methylation, and two additional DNA methylation markers to track response to DNA demethylating agents.
    • Direct Comprehensive DNA methylation analysis.
    • Gene expression profiling to assess genetic changes.
Same as current
Not Provided
Not Provided
 
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

This is a Phase I study with a conditional cohort expansion phase to evaluate the feasibility of, and to obtain preliminary efficacy data about, pretreatment with Azacytidine (AZA) for 5 days followed by fludarabine/cytarabine chemotherapy regimen in pediatric acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients who are refractory to primary treatment or who relapsed.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Lymphoblastic Leukemia, Acute, Childhood
  • Myelogenous Leukemia, Acute, Childhood
  • Drug: Azacitidine
    Dose assigned at study entry. Azacytidine will be given subcutaneously, once daily on days 1 to 5, for a total of 5 doses.
    Other Names:
    • 5 Azacytidine
    • Vidaza
    • Azacytidine
  • Drug: Fludarabine
    30 mg/m2/dose, intravenous infusion over 30 minutes, once daily, on days 6 to 10, total 5 doses
    Other Names:
    • fludarabine phosphate
    • Fludara
    • 2-fluoro-ara-AMP
    • Oforta
  • Drug: Cytarabine
    2000 mg/m2/dose intravenous infusion over 3 hours, starting 4 hours after the beginning of fludarabine, once daily, on days 6 to 10, total 5 doses.
    Other Names:
    • Cytosar-U
    • Ara-C
    • Arabinosylcytosine
    • cytosine arabinoside
  • Experimental: Dose Level 1
    • Azacytidine 75 mg/m2/day
    • Fludarabine 30 mg/m2/dose
    • Cytarabine 2000 mg/m2/dose
    Interventions:
    • Drug: Azacitidine
    • Drug: Fludarabine
    • Drug: Cytarabine
  • Experimental: Dose Level 0
    • Azacytidine 50 mg/m2/day
    • Fludarabine 30 mg/m2/dose
    • Cytarabine 2000 mg/m2/dose
    Interventions:
    • Drug: Azacitidine
    • Drug: Fludarabine
    • Drug: Cytarabine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
15
July 2014
July 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

Patients must be ≥ 1 and ≤ 21 years of age.

Diagnosis

  1. Patients with AML must have ≥5% blasts (by morphology) in the bone marrow.
  2. Patients with ALL must have an M2 or M3 marrow (≥5% blasts by morphology).
  3. Patients may have disease in the central nervous system (CNS) or other sites of extramedullary disease. No cranial irradiation is allowed during the protocol therapy.
  4. Patients with secondary AML are eligible.
  5. Patients with Down syndrome and DNA fragility syndromes (such as Fanconi anemia, Bloom syndrome) are excluded.

Karnofsky > 50% for patients > 16 years of age and Lansky > 50% for patients ≤ 16 years of age.

Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

Myelosuppressive chemotherapy - the eligibility criteria is different between phase I and expansion phase

  1. Phase I

    • Any patient with AML in 1st or greater relapse, OR
    • Any patient with ALL in 2nd or greater relapse, OR
    • Patients with AML or ALL failed to go into remission after first or greater relapse, OR
    • Patients with AML or ALL failed to go into remission from original diagnosis after two or more courses of induction attempts.
  2. Expansion phase - will be restricted to AML patients only
  3. Cytoreduction with hydroxyurea can be initiated and continued for up to 24 hours prior to the start of azacytidine. It is recommended to use hydroxyurea in patients with significant leukocytosis (WBC > 50,000/L) to control blast count before initiation of systemic protocol therapy.
  4. Patients who relapsed while they are receiving cytotoxic therapy (including AZA , decitabine, or vorinostat) At least 14 days must have elapsed since the completion of the cytotoxic therapy.

Hematopoietic stem cell transplant: Patients who have experienced their relapse after a stem cell transplant are eligible, provided they have no evidence of acute or chronic Graft-versus-Host Disease (GVHD) and are at least 90 days post-transplant at the time of enrollment.

Hematopoietic growth factors: It must have been at least 7 days since the completion of therapy with filgrastim or other growth factors at the time of enrollment. It must have been at least 14 days since the completion of therapy with pegfilgrastim (Neulasta®).

Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair

Monoclonal antibodies: At least 3 half-lives of the antibody must have elapsed after the last dose of monoclonal antibody. (i.e. Gemtuzumab = 36 days)

Immunotherapy: At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines.

Radiation Therapy (XRT): Craniospinal XRT is prohibited during protocol therapy. No washout period is necessary for radiation given to non-CNS chloromas; ≥ 90 days must have elapsed if prior total body radiation or craniospinal radiation.

Renal and hepatic function

Patients must have adequate renal and hepatic functions as indicated by the following laboratory values:

  • Patient must have a calculated creatinine clearance or radioisotope glomerular filtration rate (GFR) greater than or equal to 70ml/min/1.73m2 OR a normal serum creatinine based on age/gender.
  • Direct bilirubin < 1.5 x upper limit of normal (ULN) for age or normal, AND alanine transaminase (ALT) < 5 x ULN for age.

Adequate Cardiac Function Defined as: Shortening fraction greater than or equal to 27% by echocardiogram, OR ejection fraction greater than or equal to 50% by radionuclide angiogram (MUGA).

Reproductive Function

  • Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed within 2 weeks prior to enrollment.
  • Female patients with infants must agree not to breastfeed their infants while on this study.
  • Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for a minimum of 6 months after study treatment.

Patients and/or their parents or legal guardians must be capable of understanding the investigational nature, potential risks and benefits of the study. All patients and/or their parents or legal guardians must sign a written informed consent.

Exclusion Criteria:

Patients will be excluded if they have a known allergy to any of the drugs used in the study.

Patients will be excluded if they have a systemic fungal, bacterial, viral or other infection that is exhibiting ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment. The patient needs to be off pressors and have negative blood cultures for 48 hours.

Patients will be excluded if there is a plan to administer non-protocol chemotherapy, radiation therapy, or immunotherapy during the study period.

Patients will be excluded if they have significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance with the protocol treatment or procedures, interfere with consent, study participation, follow up, or interpretation of study results.

Patients with Down syndrome and DNA fragility syndromes (such as Fanconi anemia, Bloom syndrome) are excluded.

Both
1 Year to 21 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Canada
 
NCT01861002
T2011-002
Yes
Weili Sun, Children's Hospital Los Angeles
Therapeutic Advances in Childhood Leukemia Consortium
  • Gateway for Cancer Research
  • University of Southern California
Study Chair: Weili Sun, MD, PhD Children's Hospital Los Angeles
Therapeutic Advances in Childhood Leukemia Consortium
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP